首页> 美国卫生研究院文献>International Journal of Nanomedicine >Bile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating
【2h】

Bile salt/phospholipid mixed micelle precursor pellets prepared by fluid-bed coating

机译:流化床包衣制备胆汁盐/磷脂混合胶束前体颗粒

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Bile salt/phospholipid mixed micelles (MMs) are potent carriers used for oral absorption of drugs that are poorly soluble in water; however, there are many limitations associated with liquid formulations. In the current study, the feasibility of preparing bile salt/phospholipid MM precursor (preMM) pellets with high oral bioavailability, using fluid-bed coating technology, was examined. In this study, fenofibrate (FB) and sodium deoxycholate (SDC) were used as the model drug and the bile salt, respectively. To prepare the MMs and to serve as the micellular carrier, a weight ratio of 4:6 was selected for the sodium deoxycholate/phospholipids based on the ternary phase diagram. Polyethylene glycol (PEG) 6000 was selected as the dispersion matrix for precipitation of the MMs onto pellets, since it can enhance the solubilizing ability of the MMs. Coating of the MMs onto the pellets using the fluid-bed coating technology was efficient and the pellets were spherical and intact. MMs could be easily reconstituted from preMM pellets in water. Although they existed in a crystalline state in the preMM pellets, FB could be encapsulated into the reconstituted MMs, and the MMs were redispersed better than solid dispersion pellets (FB:PEG = 1:3) and Lipanthyl®. The redispersibility of the preMM pellets increased with the increase of the FB/PEG/micellar carrier. PreMM pellets with a FB:PEG:micellar carrier ratio of 1:1.5:1.5 showed 284% and 145% bioavailability relative to Lipanthyl® and solid dispersion pellets (FB:PEG = 1:3), respectively. Fluid-bed coating technology has considerable potential for use in preparing sodium deoxycholate/phospholipid preMM pellets, with enhanced oral bioavailability for poorly water-soluble drugs.
机译:胆汁盐/磷脂混合胶束(MMs)是有效的载体,用于口服吸收难溶于水的药物。但是,液体制剂有许多限制。在当前的研究中,研究了使用流化床包衣技术制备具有高口服生物利用度的胆汁盐/磷脂MM前体(preMM)颗粒的可行性。在这项研究中,非诺贝特(FB)和脱氧胆酸钠(SDC)分别用作模型药物和胆汁盐。为了制备MM并用作微细胞载体,基于三元相图,将脱氧胆酸钠/磷脂的重量比选择为4:6。选择聚乙二醇(PEG)6000作为MM沉淀到颗粒上的分散基质,因为它可以增强MM的溶解能力。使用流化床包衣技术将MMs包被到药丸上是有效的,药丸是球形且完整的。 MM可以很容易地从水中的preMM颗粒中复原。尽管它们在preMM颗粒中以结晶状态存在,但FB可以封装到重构的MM中,并且与固体分散颗粒(FB:PEG = 1:3)和Lipanthyl®相比,MM的分散性更好。 preMM粒料的可再分散性随FB / PEG /胶束载体的增加而增加。 FB:PEG:胶束载体比例为1:1.5:1.5的PreMM颗粒相对于Lipanthyl®和固体分散体颗粒(FB:PEG = 1:3)分别显示284%和145%的生物利用度。流化床包衣技术在制备脱氧胆酸钠/磷脂preMM药丸中具有巨大的潜力,对于水溶性差的药物,口服生物利用度也有所提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号